Journal of diabetes and its complications · 2026
Significant decrease of serum extracellular vesicle neuropilin-1 in type 2 diabetes mellitus patients with endothelial dysfunction: a cross-sectional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cui Zhengshuo, Zhang Zihang, Li Xinxin, Liu Yang, Zhou Weiwei, Guo Han, Tang Jieqiong, Zeng Zhechun, Yuan Hui, Hu Rong, Tao Hong, Li Linghai, Zhang Huina
Аннотация
AIMS: To investigate the association between serum extracellular vesicle-derived neuropilin-1 (EV NRP1) and endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM).
METHODS: In this cross-sectional study, 164 hospitalized patients with type 2 diabetes mellitus underwent Endo PAT testing and were classified into endothelial dysfunction and normal endothelial function groups according to the reactive hyperemia index (RHI). Serum extracellular vesicles were isolated using a precipitation-based kit. Serum extracellular vesicle-derived neuropilin-1 and serum neuropilin-1 concentrations were measured using a flow cytometric multiplex assay.
RESULTS: EV NRP1 levels were significantly lower in the endothelial dysfunction group than in the normal endothelial function group (207.69 ± 142.97 vs. 271.89 ± 174.07 ng/mL, P = 0.015), and serum NRP1 showed a similar decreasing trend (206.10 ± 48.35 vs. 223.22 ± 49.03 ng/mL, P = 0.030). EV NRP1, rather than serum NRP1, was positively correlated with RHI and LnRHI. Higher EV NRP1 was independently associated with lower odds of endothelial dysfunction (OR = 0.627, 95% CI 0.417-0.944; P = 0.025).
CONCLUSIONS: EV NRP1 levels are reduced and independently associated with endothelial dysfunction in patients with T2DM, supporting its potential as a biomarker for diabetic endothelial dysfunction.
METHODS: In this cross-sectional study, 164 hospitalized patients with type 2 diabetes mellitus underwent Endo PAT testing and were classified into endothelial dysfunction and normal endothelial function groups according to the reactive hyperemia index (RHI). Serum extracellular vesicles were isolated using a precipitation-based kit. Serum extracellular vesicle-derived neuropilin-1 and serum neuropilin-1 concentrations were measured using a flow cytometric multiplex assay.
RESULTS: EV NRP1 levels were significantly lower in the endothelial dysfunction group than in the normal endothelial function group (207.69 ± 142.97 vs. 271.89 ± 174.07 ng/mL, P = 0.015), and serum NRP1 showed a similar decreasing trend (206.10 ± 48.35 vs. 223.22 ± 49.03 ng/mL, P = 0.030). EV NRP1, rather than serum NRP1, was positively correlated with RHI and LnRHI. Higher EV NRP1 was independently associated with lower odds of endothelial dysfunction (OR = 0.627, 95% CI 0.417-0.944; P = 0.025).
CONCLUSIONS: EV NRP1 levels are reduced and independently associated with endothelial dysfunction in patients with T2DM, supporting its potential as a biomarker for diabetic endothelial dysfunction.